Clinical trial NCT03618602: Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients
Official title: A Phase I Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Refractory Multiple Myeloma
Recurrent Multiple Myeloma
Lead sponsor: Shanghai Theorion Pharmaceutical Co Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
First posted: 2018-08-07
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and efficacy of Bisthianostat in refractory or recurrent multiple myeloma patients.

Detailed description: This is a first-in-human, single center, open-label, single arm, dose escalating phase I study. This study will be conducted in 3 parts.

Phase A : Patients will receive single dose of bisthianostat to evaluate the single-dose pharmacokinetics and safety.

Phase B: After single-dose phase, patients will receive multiple dose bisthianostat for 4 weeks on day 1,4,11,14,18,21,25,28 to evaluate the multiple-dose pharmacokinetics and safety

Phase C: Patients will continue on the study if they benefit from the drug and not experience any serious side effects.

Eligibility criteria: Inclusion Criteria:

* Diagnosed as stage II or III (Durie-Salmon Staging System) multiple myeloma with disease progression or recurrence after at least two cycles of systemic antimyeloma treatment.
* Serum M protein≥ 5.0g / L, or urine M protein ≥ 200mg / 24h, or serum free light chain ≥ 200mg / L.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
* Expected survival of ≥3 months.
* Female participants of childbearing potential should have negative urine pregnancy test in screening period (accept previous test result within 14 days before screening), and must agree to adopt effective contraceptive measures within 14 days before receiving first dose of study drug, during the treatment period and within 28 days after final dose of study drug.
* Male participants must agree to adopt effective contraceptive measures and not allowed to donate sperms during the treatment period, and within 28 days after final dose of study drug.
* Hemoglobin ≥ 80 g/L, Platelet≥50×109/L (50,000/mm3), Absolute Neutrophil Count≧1.0×109/L (1000 cells/mm3), Prothrombin time(PT) and activated partial thromboplastin time ≤ 2 x Upper Limit of Normal (ULN)
* AST or ALT ≤ 1.5 x ULN, total bilirubin≤ 1.5 x ULN;
* Serum Creatinine ≤ 1.5 x ULN, glomerular filtration rate≥ 50 ml/min;
* NYHA Class I or II
* Written informed consent obtained prior to participation in the study

Exclusion Criteria:

* Pregnant or lactating women.
* Non-secretory multiple myeloma patients.
* Plasma cell leukemia patients.
* Received any anti-cancer medication or experimental drugs against multiple myeloma within 1 week before first dose of bisthianostat, any experimental treatment other than medication (eg. leukocyte donor/monocyte infusion) within 56 days before first dose of bisthianostat. Participation in any other drug or medical devices within 56 days before the study.
* Stem cell transplant planned on the following 28 days.
* Uncontrolled hypercalcemia after treatments, eg. saline infusion.
* Renal insufficiency required hemodialysis or peritoneal dialysis.
* NCI-CTCAE grade 2 Peripheral Neuropathy.
* Serious heart disease in the past 6 months, including angina requiring surgery, uncontrolled hypertension after anti-hypertensive treatments (Systolic blood pressure\> 160 mmHg, Diastolic blood pressure\>90mmHg); Myocardial infarction; Grade II-IV congestive heart failure; unstable angina.
* HIV, HCV or HBV (HBV-DNA \> 20 IU/mL) infection.
* Patients with any other prior malignancy, except for skin basal cell carcinoma, cervical carcinoma in situ, breast carcinoma in situ, skin squamous cell carcinoma that have been treated and controlled.
* Imaging evidences show tumors have involved main blood vessels and nerves.
* Patients with significant central nervous system lesions.
* Patients with mental illness.
* Patients with history of alcohol or drug abuse, patients with allergy to the active ingredient or excipients of study drug, and patients who are unable or unwilling to receive the intravenous administration.
* Active infection (Bacteria, fungi, virus etc), fever with body temperature \> 38 ℃ for reasons unknown.
* Other situations that investigator considers it's inappropriate for patients to participate in this study.

Primary outcomes:
measure: Maximum tolerated dose of Bisthianostat
timeFrame: Up to 24 months
measure: Treatment-related adverse events considered as dose-limiting toxicity
timeFrame: During the first cycle (4 weeks)
Secondary outcomes:
measure: Peak Plasma Concentration (Cmax)
timeFrame: During the first cycle (4 weeks)
measure: Area under the plasma concentration versus time curve (AUC)
timeFrame: During the first cycle (4 weeks)
measure: Time of Peak Concentration (Tmax)
timeFrame: During the first cycle (4 weeks)
measure: Half life (T1/2)
timeFrame: During the first cycle (4 weeks)
measure: Objective Response Rate
timeFrame: Up to 1 month after last dose
measure: Incidence of adverse events related to treatments
timeFrame: Up to 1 month after last dose
measure: Incidence of laboratory abnormalities related to treatments
timeFrame: Up to 1 month after last dose
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Renji Hospital
state: Shanghai
Study officials:
affiliation: RenJi Hospital
name: Jian Hou, MD
role: PRINCIPAL_INVESTIGATOR
References: